PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis

68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour

(2017) Christian Uprimny et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer

(2017) R. Yates Coley et al.   EUROPEAN UROLOGY

Immunohistochemical Validation of PSMA Expression Measured by68Ga-PSMA PET/CT in Primary Prostate Cancer

(2017) Nadine Woythal et al.   JOURNAL OF NUCLEAR MEDICINE

Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer

(2016) Matthias Eiber et al.   EUROPEAN UROLOGY

Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy

(2016) Lars Budäus et al.   EUROPEAN UROLOGY

Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis

(2016) Marlon Perera et al.   EUROPEAN UROLOGY

Clarifying the PSA grey zone: The management of patients with a borderline PSA

(2016) Talisa Ross et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer

(2016) W. P. Fendler et al.   JOURNAL OF NUCLEAR MEDICINE

Diagnostic Efficacy of 68Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer

(2016) Tobias Maurer et al.   JOURNAL OF UROLOGY

18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide

(2015) Ugo De Giorgi et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients

(2015) Vincenza Conteduca et al.   Future Oncology

68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies

(2015) M. Weineisen et al.   JOURNAL OF NUCLEAR MEDICINE

Aggressive Variants of Castration-Resistant Prostate Cancer

(2014) H. Beltran et al.   CLINICAL CANCER RESEARCH

Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies

(2014) Vincenza Conteduca et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors

(2009) T John et al.   ONCOGENE